Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7411 to 7425 of 8314 results

  1. Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007

    In development Reference number: GID-TA11567 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113

    In development Reference number: GID-TA11025 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]

    Discontinued Reference number: GID-TA10926

    Technology appraisal guidance
    Discontinued

  4. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

    Technology appraisal guidance
    Discontinued

  5. Atopic Dermatitis (Eczema)

    Discontinued Reference number: GID-NG10289

    NICE guideline
    Discontinued

  6. Breathlessness

    Discontinued Reference number: GID-NG10387

    NICE guideline
    Discontinued

  7. Haemochromatosis

    Discontinued Reference number: GID-NG10287

    NICE guideline
    Discontinued

  8. Reducing the mortality and morbidity for healthcare associated infections

    Discontinued Reference number: GID-NG10059

    NICE guideline
    Discontinued

  9. Acute bowel obstruction

    Discontinued Reference number: GID-NG10377

    NICE guideline
    Discontinued

  10. Type 2 diabetes in adults: management - insulin therapy

    Discontinued Reference number: GID-NG10375

    NICE guideline
    Discontinued

  11. Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]

    In development Reference number: GID-TA11646 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]

    In development Reference number: GID-TA11712 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pralsetinib for thyroid cancer [ID4018]

    Discontinued Reference number: GID-TA10910

    Technology appraisal guidance
    Discontinued

  14. Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

    Discontinued Reference number: GID-HST10032

    Highly specialised technologies guidance
    Discontinued

  15. LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

    Discontinued Reference number: GID-TA10728

    Technology appraisal guidance
    Discontinued